Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug containing chymase inhibitor as the active ingredient

A chymotrypsin-like and chymotrypsin-like technology, which is applied in the field of medicines containing chymotrypsin-like inhibitors as active ingredients

Inactive Publication Date: 2006-11-29
TEIJIN PHARMA CO LTD
View PDF17 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has also been reported that there are almost no mast cells in the pancreas or kidney ("Mast Cell distribution inrats" Arzneimittelforschung, (Germany) 1994, 44 volumes, 3 phases, 370 pages), and about The relationship between pancreatic beta cells and mast cells or the effect of chymotrypsin on insulin secretion has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug containing chymase inhibitor as the active ingredient
  • Drug containing chymase inhibitor as the active ingredient
  • Drug containing chymase inhibitor as the active ingredient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0235] Improving Effects of Impaired Glucose Tolerance

[0236] 22 weeks of wild-type mice (C57Black) (Wild), TGM (mice expressing human chymotrypsin gene in it) and by mixing 0.1% chymotrypsin inhibitor (Chymase Inhibitor: ChI, compound number 58 Sulfate, the IC of compound 58 50 The value is 1nM-10nM) from 10 weeks to 12 consecutive weeks of TGM (TGM / ChI) 3 groups, orally administered 1.5g / kg of glucose after overnight fasting, blood glucose concentration and insulin concentration after 60 minutes were measured .

[0237] result:

[0238] At 60 minutes after the sugar load, the blood glucose concentrations were 119±20 mg / dl for Wild, 181±22 mg / dl for TGM, and 134±18 mg / dl for TGM / ChI* (mean±standard deviation, for Wild*pfigure 1 ).

[0239] On the other hand, the blood insulin concentration at the same time was 386±97ng / l for Wild, 809±228ng / l for TGM, and 425±158ng / l for TGM / ChI (mean±standard deviation). Glucose concentration also increased significantly, but showed a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An agent for improving abnormal glucose tolerance or a preventive and / or a remedy for diseases caused by abnormal glucose tolerance containing a chymase inhibitor as the active ingredient. Examples of the diseases caused by abnormal glucose tolerance include diabetes and / or complications of diabetes. Examples of the complications of diabetes include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinemia, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, vasculitis, brain infarction, hypertension, renal insufficiency, neuropathy, nephritis, renal aneurysm, renal infarction, obesity and so on.

Description

technical field [0001] The present invention relates to a drug containing a chymase inhibitor as an active ingredient, which is an agent for improving abnormal glucose tolerance or a preventive and / or therapeutic agent for diseases caused by abnormal glucose tolerance. [0002] More specifically, the present invention relates to a medicine suitable for diseases caused by abnormal glucose tolerance. The diseases caused by abnormal glucose tolerance refer to diabetes and / or diabetic complications, wherein diabetic complications refer to diabetic nephropathy, diabetic retinopathy, diabetic peripheral nerve disorder, hyperinsulinemia, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, vasculitis, cerebral infarction, hypertension, nephropathy, nephritis, renal aneurysm, renal infarction or obesity. Background technique [0003] Impaired glucose tolerance refers to insufficiency of insulin secretory response due to glucose load o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K45/06A61K31/4184A61P3/00A61P3/04A61P3/10A61P9/00A61P9/10A61P9/12A61P13/12A61P25/02A61P25/28A61P27/02C07D409/06A61K31/00C07D413/12
CPCA61K31/00C07D413/12A61K31/4184A61P3/00A61P3/04A61P3/10A61P9/00A61P9/10A61P9/12A61P13/12A61P25/02A61P25/28A61P27/02A61P43/00
Inventor 浦田秀则长谷直树土屋直树
Owner TEIJIN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com